Literature DB >> 23460013

Management of nontuberculous mycobacterial (NTM) lung disease.

Julie V Philley1, David E Griffith.   

Abstract

Nontuberculous mycobacterial (NTM) lung diseases present formidable obstacles to successful management, especially when compared with tuberculosis, beginning with diagnosis and extending through treatment. Factors peculiar to NTM disease such as extensive microbial resistance mechanisms and difficult to interpret, even misleading, in vitro drug susceptibility patterns are just two of the multiple and frustrating clinical management challenges. More conventional problems such as drug-drug interactions, medication side-effects, and nonadherence with therapy add further impediments to successful outcomes. In spite of these difficulties, the majority of NTM lung disease patients are still treated successfully. Because the prevalence of NTM is rising, it is increasingly necessary for clinicians to understand those unique aspects of NTM lung disease diagnosis and treatment that differ from tuberculosis and that contribute to limited treatment options. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23460013     DOI: 10.1055/s-0033-1333575

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  17 in total

1.  Synergistic Efficacy of β-Lactam Combinations against Mycobacterium abscessus Pulmonary Infection in Mice.

Authors:  Elizabeth Story-Roller; Emily C Maggioncalda; Gyanu Lamichhane
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

2.  Mycobacterium paraffinicum causing symptomatic pulmonary infection.

Authors:  Austin W Chan; Sarah Kabbani; Gerald Staton; Colleen S Kraft
Journal:  J Clin Microbiol       Date:  2014-01-22       Impact factor: 5.948

3.  Select β-Lactam Combinations Exhibit Synergy against Mycobacterium abscessus In Vitro.

Authors:  Elizabeth Story-Roller; Emily C Maggioncalda; Gyanu Lamichhane
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

4.  Clinical significance of nontuberculous mycobacteria from respiratory specimens in stem cell transplantation recipients.

Authors:  Ji Young Kang; Jick Hwan Ha; Hye Seon Kang; Hyoung-Kyu Yoon; Hee-Je Kim; Seok Lee; Dong-Gun Lee; Jung Im Jung; Seok Chan Kim; Young Kyoon Kim
Journal:  Int J Hematol       Date:  2015-02-08       Impact factor: 2.490

5.  Non-tuberculous mycobacterial infections after solid organ transplantation: a survival analysis.

Authors:  S A Longworth; E A Blumberg; T D Barton; C Vinnard
Journal:  Clin Microbiol Infect       Date:  2014-10-29       Impact factor: 8.067

Review 6.  Inhaled antibiotics for lower airway infections.

Authors:  Bradley S Quon; Christopher H Goss; Bonnie W Ramsey
Journal:  Ann Am Thorac Soc       Date:  2014-03

7.  Changes in serum immunomolecules during antibiotic therapy for Mycobacterium avium complex lung disease.

Authors:  S-Y Kim; W-J Koh; H Y Park; K Jeon; O J Kwon; S-N Cho; S J Shin
Journal:  Clin Exp Immunol       Date:  2014-04       Impact factor: 4.330

8.  Treatment of Non-Tuberculous Mycobacterial Lung Disease.

Authors:  Julie V Philley; Mary Ann DeGroote; Jennifer R Honda; Michael M Chan; Shannon Kasperbauer; Nicholas D Walter; Edward D Chan
Journal:  Curr Treat Options Infect Dis       Date:  2016-10-11

Review 9.  Clinical Phenotypes of Cystic Fibrosis Carriers.

Authors:  Philip M Polgreen; Alejandro P Comellas
Journal:  Annu Rev Med       Date:  2022-01-27       Impact factor: 13.739

Review 10.  Nontuberculous mycobacterial pulmonary infections.

Authors:  Margaret M Johnson; John A Odell
Journal:  J Thorac Dis       Date:  2014-03       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.